Welcome to our dedicated page for Lineage Cell The news (Ticker: LCTX), a resource for investors and traders seeking the latest updates and insights on Lineage Cell The stock.
Lineage Cell Therapeutics Inc. (LCTX) is a clinical-stage biotechnology leader developing novel cell-based therapies for degenerative diseases. This dedicated news hub provides investors and stakeholders with timely updates on corporate developments, clinical research progress, and regulatory milestones.
Access authoritative information about LCTX's innovative platforms in cell replacement therapies and targeted drug delivery systems. Our curated collection features press releases covering clinical trial results, strategic partnerships, intellectual property updates, and scientific presentations.
Stay informed about advancements in treatments for retinal degeneration, spinal cord injuries, and oncology applications. All content is verified at source, ensuring reliable tracking of the company's progress in regenerative medicine. Bookmark this page for streamlined access to essential updates impacting LCTX's position in the biotech sector.
Lineage Cell Therapeutics (NYSE: LCTX) announced that 36-month results from the Phase 1/2a clinical study of RG6501 (OpRegen) will be presented at Clinical Trials at the Summit (CTS) 2025. The study focuses on treating patients with geographic atrophy (GA) secondary to age-related macular degeneration (AMD). The presentation titled "OpRegen® Retinal Pigment Epithelium (RPE) Cell Therapy for Patients with Geographic Atrophy (GA): Month 36 Results from the Phase 1/2a Trial" will be delivered by Dr. Christopher D. Riemann from Cincinnati Eye Institute at the conference, scheduled for June 20-21, 2025.
Lineage Cell Therapeutics (NYSE: LCTX), a clinical-stage biotech company focused on allogeneic cell therapies for neurological conditions, has scheduled its first quarter 2025 financial results announcement for May 13, 2025, after U.S. market close. The company will host a conference call and webcast at 4:30 p.m. ET/1:30 p.m. PT on the same day to discuss the results and provide a business update.
Investors can join the call by dialing (800) 715-9871 from the U.S. and Canada. A webcast will be available in the Investors section of Lineage's website, with replay access through May 20, 2025, using conference ID 1789489.
Lineage Cell Therapeutics (LCTX) and the Christopher & Dana Reeve Foundation announce their collaboration for the 3rd Annual Spinal Cord Injury Investor Symposium (3rd SCIIS), scheduled for June 27, 2025. The event will be fully virtual for the first time to enhance accessibility for individuals with spinal cord injuries.
The symposium aims to unite companies developing SCI treatments with regulators, key opinion leaders, patients, advocacy organizations, and investors. Key discussion topics include:
- Preclinical and clinical SCI treatment approaches
- Drug development processes
- Healthcare disparities in SCI care and outcomes
- Patient perspectives in drug development
- Clinical endpoints and assessment tools
Lineage recently initiated a clinical study of their cell transplant candidate, OPC1, which aims to improve recovery and mobility by replacing cells destroyed after spinal cord injury.
Lineage Cell Therapeutics (NYSE: LCTX) announced its participation in the upcoming Eyecelerator@ Park City 2025 conference, where CEO Brian M. Culley will join a distinguished panel discussing novel drug delivery approaches for glaucoma and retina treatments.
The panel, titled 'I Shall Be Released: Novel Drug Delivery Approaches for Glaucoma and Retina', will feature representatives from REGENXBIO Inc., Regenerative Patch Technologies, and Neurotech Pharmaceuticals. The session is scheduled for May 2, 2025, from 12:30pm to 1:30pm MDT at the Grand Hyatt, Deer Valley, Utah.
The discussion will be chaired by Dr. Allen C. Ho, Eyecelerator Retina Program Director and Wills Eye Hospital Attending Surgeon. The event is sponsored by the American Academy of Ophthalmology (AAO), and the panel presentation will be made available on Lineage's website after the conference.
Lineage Cell Therapeutics (LCTX) reported its Q4 and full year 2024 financial results, highlighting significant progress across multiple programs. The company's lead asset OpRegen, developed in collaboration with Roche and Genentech, received RMAT designation from FDA for geographic atrophy treatment.
Financial highlights include:
- Q4 2024 revenues of $2.9M (up from $2.1M in Q4 2023)
- Full year 2024 revenues of $9.5M (up from $8.9M in 2023)
- Q4 net loss of $3.3M ($0.02 per share)
- Full year net loss of $18.6M ($0.09 per share)
- Cash position of $47.8M as of December 31, 2024
The company completed two financings totaling $44M in gross proceeds, with potential for additional $36M from warrant exercises. Current cash runway extends into Q1 2027. Operating expenses decreased to $31.0M in 2024 from $33.7M in 2023, reflecting improved operational efficiency.
Lineage Cell Therapeutics (NYSE American and TASE: LCTX), a clinical-stage biotechnology company focused on allogeneic cell therapies for neurological conditions, has scheduled its fourth quarter and full year 2024 financial results announcement for March 10, 2025, after U.S. market close.
The company will host a conference call and webcast at 4:30 p.m. Eastern Time/1:30 p.m. Pacific Time on the same day. Investors can join via phone at (800) 715-9871 from the U.S. and Canada, requesting the 'Lineage Cell Therapeutics Call'. A webcast will be available in the Investors section of the company's website, with replay access through March 17th, 2025 (conference ID: 6707203).
Lineage Cell Therapeutics (NYSE: LCTX) has initiated the DOSED clinical study to evaluate a novel delivery device for OPC1, their investigational stem cell-derived transplant for spinal cord injury (SCI). The study will assess the safety and utility of the Manual Inject Parenchymal Spinal Delivery System (MI PSD System) for delivering OPC1 to injury sites.
The DOSED study will include both subacute (21-42 days post-injury) and chronic (1-5 years post-injury) SCI patients, marking the first time OPC1 will be tested in chronic cases. OPC1 has already demonstrated a strong safety profile in two previous clinical trials: a five-patient Phase 1 safety trial in acute thoracic SCI with 13+ years of follow-up, and a 25-patient Phase 1/2a trial in subacute cervical SCI with 7+ years of follow-up.
The new delivery system allows administration over several minutes without interrupting patient ventilation and is compatible with a new immediate-use formulation of OPC1. The first study site will be UC San Diego Health.
Lineage Cell Therapeutics (NYSE American and TASE: LCTX), a clinical-stage biotechnology company focused on developing allogeneic cell therapies for neurological conditions, has announced its participation in the upcoming Oppenheimer 35th Annual Healthcare Lifesciences Conference.
The company's CEO, Brian M. Culley, is scheduled to present on February 11, 2025, at 12:40pm ET. The conference will be held virtually from February 11-12, 2025. Interested parties will be able to access a replay of the presentation through the Events and Presentations section of Lineage's website, with additional video content available on the company's Media page.
Lineage Cell Therapeutics (NYSE: LCTX) has completed the second tranche of its previously announced registered direct offering, receiving an additional $6 million in gross proceeds. This follows the first tranche closure in November 2024, which brought in $24 million. The total gross proceeds received now stand at $30 million.
The company could receive up to an additional $36 million upon full exercise of OpRegen® clinical milestone-linked warrants. The second tranche involved issuing 7,894,737 common shares with accompanying warrants to Broadwood Partners at $0.76 per share. The warrants are exercisable at $0.91 per share starting May 21, 2025, expiring on May 21, 2028, or 90 days after announcing intent to advance OpRegen into a phase 2 or 3 clinical trial.
Lineage Cell Therapeutics (NYSE American and TASE: LCTX), a clinical-stage biotech firm developing allogeneic cell therapies, has published a letter to shareholders detailing recent achievements and its 2025 outlook. Lineage specializes in cell transplants, using mature, differentiated cells to replace lost or dysfunctional cells in conditions like dry age-related macular degeneration (dry-AMD). Their lead program, OpRegen, is in a Phase 2a trial in partnership with Roche and Genentech.
Lineage's financing strategy has secured $24 million in gross proceeds with an additional $6 million expected, extending their operational runway into Q1 2027. They have also issued warrants for up to $36 million, contingent on OpRegen’s advancement. The company aims to demonstrate scalable manufacturing capabilities, aspiring to produce thousands of doses from a single donor.
Looking ahead, Lineage plans to support OpRegen’s development while advancing its other programs, including OPC1 for spinal cord injuries and ReSonance™ for hearing loss. The company emphasizes its potential for long-term value creation through its unique cell transplant approach.
FAQ
What is the current stock price of Lineage Cell The (LCTX)?
What is the market cap of Lineage Cell The (LCTX)?
